Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study


To cite this version:


HAL Id: hal-02452540
https://hal.archives-ouvertes.fr/hal-02452540
Submitted on 23 Jan 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.
Effect of the Bolsa Familia Programme on the outcome of tuberculosis treatment: a prospective cohort study

Janaina Gomes Nascimento Oliosi, Barbara Reis-Santos, Rodrigo Leite Locatelli, Carolina Maia Martins Sales, Walter Gomes da Silva Filho, Kerollen Cristina da Silva, Mauro Niskier Sanchez, Kaio Vinicius Freitas de Andrade, Gleide Santos de Araújo, Priya B Shete, Susan Martins Pereira, Lee W Riley, Christian Lienhardt, Ethel Leonor Noia Maciel

Summary

Background Social protection interventions might improve tuberculosis outcomes and could help to control the epidemic in Brazil. The aim of this study was to evaluate the independent effect of the Bolsa Familia Programme (BFP) on tuberculosis treatment outcomes in Brazil.

Methods We prospectively recruited and followed up individuals (aged ≥18 years) who initiated tuberculosis treatment at 42 health-care centres across seven cities in Brazil, between March 1, 2014, and April 30, 2017. Patients were interviewed at health-care centres and information about individual characteristics, socioeconomic status, living conditions, lifestyle, and comorbidities was recorded. Patients were separated into two groups according to BFP beneficiary status: BFP (exposed) or non-BFP (not exposed). Treatment outcome (cure, dropout, death, or development of drug-resistant tuberculosis or treatment failure) was recorded after 6 months of therapy. Pearson’s χ² test and ANOVA were used to compare tuberculosis treatment outcomes between the two groups, and we estimated the propensity score of being a beneficiary of the BFP using a logit model. We used multinomial regression models to evaluate the effect of the BFP on tuberculosis treatment outcomes.

Findings 1239 individuals were included in the study, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not. After 6 months of treatment, 912 (87%) of 1043 patients in the non-BFP group and 173 (88%) of 196 patients in the BFP group were cured of tuberculosis, 103 (10%) patients in the non-BFP group and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group and six (3%) patients in the BFP group had died. Three (<1%) of 1043 patients in the non-BFP group developed drug-resistant tuberculosis. Being a BFP beneficiary had a positive effect for cure (average effect 0·076 [95% CI 0·037 to 0·11]) and a negative effect for dropout (–0·070 [–0·105 to 0·036]) and death (–0·002 [–0·021 to 0·017]).

Interpretation BFP alone had a direct effect on tuberculosis treatment outcome and could greatly contribute to the goals of the WHO End TB Strategy.

Funding Brazilian National Council for Scientific and Technological Development (CNPq) and Brazilian Ministry of Health Department of Science and Technology (DECIT).

Copyright © 2018 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license.

Introduction Globally, tuberculosis remains a considerable threat to public health. In 2016, the disease was the leading cause of death due to infectious disease worldwide, with an estimated 10·4 million new cases and 1·4 million deaths. In Brazil, where the burden of tuberculosis is high, 66706 new tuberculosis cases and 4543 deaths attributed to tuberculosis were reported in 2016. Although the number of tuberculosis cases, and the associated incidence and mortality in Brazil has decreased in the past 15 years, important challenges remain for sustaining improvements in tuberculosis prevention and care. For example, the rate of cure for tuberculosis is low among patients who initiate treatment and the number of patients who discontinue treatment is high. In Brazil in 2016, the rate of cure for tuberculosis was 72% and the treatment dropout rate was 10%, exceeding that recommended by WHO (<5%), which might perpetuate transmission and poor patient outcomes. A crucial barrier to improving tuberculosis treatment outcomes might be associated with unaddressed socioeconomic factors that affect either patient adherence to care or effectiveness of treatment.

The association between poverty and tuberculosis is evident in the global distribution of the disease; the 30 countries with the highest burden of tuberculosis are also those with largest social inequality measures and the lowest income per capita. Socioeconomic conditions and social determinants are well known risks for tuberculosis infection, reactivation, and for sustaining the epidemic within populations. Research to address the effect of poverty on tuberculosis outcomes and to understand further how targeted interventions might reduce tuberculosis risk is a burgeoning area of research.
Social protection interventions aimed at reducing a patient’s social or economic risk might improve tuberculosis outcomes and contribute to curbing the epidemic.7 Used in combination with tuberculosis prevention and care activities, social protection interventions are thought to have various synergistic effects on tuberculosis treatment outcomes.8 Improvement in living conditions, improved nutrition, better psychosocial health, and access to health services can reduce susceptibility to disease and improve access to good quality tuberculosis care.9 What is less clear is how best to implement social protection interventions to maximise the social, economic, and public health impact for susceptible patients.10 Although several studies from Nigeria,11 Moldova,12 and Peru13 have shown that financial incentives are effective in improving treatment success among patients with tuberculosis, the generalisability and use of social protection interventions is context dependent.

Brazil has one of the largest conditional cash transfer programmes in the world, focused on productive inclusion (ie, programmes aimed at alleviating poverty by increasing income and employment opportunities) termed the Bolsa Família Programme (BFP). The programme represents an unprecedented initiative to address social inequalities in Brazil,14 and is an extension of the Bolsa Familia Programme (BFP), which has been responsible for considerable improvements in socioeconomic conditions in Brazil since 2006.15 The BFP, a conditional cash transfer programme, provides financial aid for families defined as poor (per capita monthly income US$25·60–51·20) with pregnant or lactating women and children and adolescents aged 17 years or younger, and all extremely poor families (per capita monthly income ≤US$25·60). The amount of money received per family is dependent on income and composition of the family, but all families receive at least a monthly basic benefit of US$25·60.16 The BFP has been shown to reduce extreme poverty, alleviate social and economic inequalities,17,18 and improve public health outcomes, including improved nutritional status of the beneficiary population19 and reduced infant mortality.20 Lower tuberculosis incidence has been found to correlate with areas of high BFP coverage.21 However, the association between BFP and tuberculosis treatment outcome remains unclear. Previously, secondary data22
have been retrospectively analysed to investigate the associations between BFP and tuberculosis outcomes in Brazil. These studies did not use an explicit theoretical model with adequate adjustment for confounding factors that influence treatment outcome. Therefore, the findings of these studies cannot be used to make inferences regarding the independent effect of BFP on tuberculosis treatment outcomes. Therefore, we did a prospective cohort analysis to evaluate the independent effect of BFP on tuberculosis treatment outcomes in Brazil.

Methods

Study design and participants

We did a prospective cohort study of individuals who had initiated treatment for tuberculosis at 42 health-care centres in seven cities (Manaus, Fortaleza, Recife, Salvador, Vitoria, Sao Paulo, and Porto Alegre) in Brazil between March 1, 2014, and April 30, 2017. The seven cities were selected because they had the highest incidence of tuberculosis nationally in 2012, and are highly representative of all administrative regions in Brazil, with regard to the socioeconomic and demographic composition of the population. Health-care centres were included if they had a treatment success rate for tuberculosis that was less than the WHO target of 85%, at least 20 individuals were diagnosed with tuberculosis at the centre in the year before data collection, and tuberculosis was treated in accordance with the National Tuberculosis Program of the Brazilian Ministry of Health recommendations.13 Health-care centres were excluded if there was an ongoing study at the health centre.

Tuberculosis was defined on the basis of at least one positive smear using acid-fast bacilli microscopy or culture or rapid molecular tuberculosis test, and also any suspected case that did not meet the laboratory confirmation criterion but presented test results or histological findings suggestive of tuberculosis (pulmonary or extra-pulmonary).22

Participants were aged 18 years or older, had microbiological diagnosis of tuberculosis by sputum smear microscopy and culture or Xpert MTB/RIF assay (Cepheid, Sunnyvale, CA, USA) and had initiated treatment for tuberculosis. Individuals who had resistant or multidrug-resistant tuberculosis, had been treated for more than 6 months for a previous episode of tuberculosis, or had received treatment in another unit for more than 30 days were excluded. Previously trained health-care workers enrolled participants during their visits to the health-care centres. Individuals were interviewed at the time of treatment initiation. All individuals provided written informed consent. The study was approved by the ethics committee of the Federal University of Espirito Santo.

Procedures

All participants were prospectively followed up for the entire tuberculosis treatment course. Trained health-care workers did surveys and health assessments at enrolment, and during the second and sixth month of tuberculosis treatment, with the exception of Salvador, where data collection was coordinated by a team from the Federal University of Bahia (Salvador, Brazil). Information about individual characteristics (sex, age, ethnicity), socioeconomic status (years of education, occupational status, monthly income, household goods), living conditions (sewerage system, waste collection, housing conditions), current lifestyle (smoking status, alcohol use, and illicit drug use), comorbidities (eg, HIV or AIDS, diabetes, kidney disease), anthropometric data, allergies, presence of bacillus Calmette-Guérin scar, previous history of tuberculosis (date of diagnosis, disease type, pharmaceutical regimen, results of examination during treatment, adverse drug reactions, response to directly observed therapy), and coverage of health insurance and receipt of social benefit (type, values) was recorded.

Treatment outcome was recorded after 6 months of therapy, when a patient is expected to be cured by the basic regimen of tuberculosis treatment. If the individuals did not complete the treatment within 6 months, they were followed up with monthly visits at the health centres until treatment completion (according to medical criteria) or if follow-up was not possible, they were removed from the study. The treatment outcome of individuals who transferred to another health service or municipality not included in the study during treatment was recovered via requests from the municipal health secretaries of each capital.

Receipt of cash transfers through the BFP was the main exposure of interest. Participants were classified as exposed (ie, BFP beneficiaries) or not exposed (ie, individuals who did not receive cash transfers from the BFP).

Outcomes were based on definitions adopted by the Brazilian Ministry of Health23 and were classified as favourable or unfavourable. Cure was defined as a favourable outcome, whereas dropout (treatment interrupted for ≥30 days), death during tuberculosis treatment from any cause, and development of drug-resistant tuberculosis or treatment failure (culture-confirmed resistance to streptomycin, isoniazid, rifampicin, or ethambutol) were defined as unfavourable outcomes. Cure was defined as medical discharge of individuals with pulmonary tuberculosis who completed their treatment and had two negative sputum smear tests, or clinical improvement and normal physical examination in patients for whom sputum smear testing was not done. Patients with extra-pulmonary tuberculosis were considered to be cured when they completed their treatment and had clinical improvement, radiological evidence, or other complementary examinations.

Statistical analysis

We required a sample size of 1200 to detect a difference in treatment outcomes of 10% between individuals that
Continuous variables (age and individual income) were presented as absolute and relative frequencies (%). Lifestyle, HIV or AIDS, comorbidities, and health insurance education, occupation, sewerage system, waste collection, and health insurance were accounted for by the clustered distribution of our sample. The average effect of being a BFP beneficiary on tuberculosis treatment outcome was estimated by a logistic model using propensity score matching in a propensity score model included the minimal number of variables identified in the directed acyclic graph, which shows how variables potentially confound the direct effect of BFP on tuberculosis treatment outcome. Propensity score indicates the probability of an individual being allocated to the exposed or non-exposed group on the basis of the covariates measured. Since BFP allocation was not random, a single comparison between beneficiaries and non-beneficiaries is not appropriate, because the effect of BFP could be associated with background characteristics, which might differ between groups. Thus, we used propensity score matching to overcome this limitation, which estimates the conditional probability of an individual being a beneficiary, according to their observed characteristics. We estimated the propensity score of being a BFP beneficiary using a logit model. The predictors in the propensity score model included the minimal number of variables needed to estimate the direct effect of the BFP on tuberculosis treatment outcomes, according to the directed acyclic graph: socioeconomic status (household goods, years of education, monthly individual income, and unemployment), environmental characteristics (waste collection and house condition), behaviour (smoking status and illicit drug use), comorbidities, and access to health-care services (private health insurance and type of health-care service during treatment).

We used multinomial regression models to assess the effect of the BFP on tuberculosis treatment outcomes, which included cure as the reference category. The first model was unadjusted, the second model was adjusted by a minimal set of variables identified in the directed acyclic graph, and the third model was adjusted by the estimated propensity score as a continuous variable. To verify the performance of the built propensity score, the second and the third models were compared. The estimation of variance–covariance matrix of all models was accounted for by the clustered distribution of our sample.

The average effect of being a BFP beneficiary on tuberculosis treatment outcome was estimated by a logistic model using propensity score matching in a directed acyclic graph: socioeconomic status (household goods, years of education, monthly individual income, and unemployment), environmental characteristics (waste collection and house condition), behaviour (smoking status and illicit drug use), comorbidities, and access to health-care services (private health insurance and type of health-care service during treatment).
1:1 ratio (pairs of observations were considered a match if the absolute difference in the propensity score was <0·05). In this analysis, outcomes were dichotomous (cure vs not cured; dropout vs not dropout; and death vs not death). The propensity score balance was analysed before and after matching. Statistical analysis was done using Stata (version 14.0).

Role of the funding source
The funders of the study had no role in study design, data collection, data interpretation, or writing of the report. The corresponding had full access to all the data in the study and had final decision to submit for publication.

Results
We enrolled 1252 individuals, of whom 13 were excluded during the follow-up period because they were diagnosed with another disease and thus were considered false-positives. We included 1239 individuals in the analysis, of whom 196 (16%) were beneficiaries of the BFP and 1043 (84%) were not. Baseline characteristics of the study population are shown in table 1. After 6 months of treatment, 912 (87%) of 1043 patients in the non-BFP group and 173 (88%) of 196 patients in the BFP group were cured of tuberculosis, 103 (10%) patients in the non-BFP group and 17 (9%) patients in the BFP group had dropped out, and 25 (3%) patients in the non-BFP group and six (3%) patients in the BFP group had died (table 2). Three (<1%) of 1043 patients in the non-BFP group developed drug-resistant tuberculosis. We identified the minimum number of variables required to test the hypothesis of a direct BFP effect on tuberculosis treatment outcomes (figure 1). Multinomial regression models using cure as the reference category showed that the relative risk of dropping out was 0·65 (95% CI 0·41–1·03) and the relative risk of death was 1·13 (0·31–4·12) in the BFP group when compared with the non-BFP group (table 3).
Being a BFP beneficiary had a positive effect for cure (average effect 0.076 [95% CI 0.037 to 0.116]) and a negative effect for dropout (−0.070 [−0.105 to −0.036]) and death (−0.002 [−0.021 to 0.017]; Table 4). These results indicate that the rate of cure is 7-6% higher in the BFP group than the non-BFP group and the proportion of patients who dropped out was 7% lower in the BFP group than the non-BFP group. To estimate the average effect of the BFP on treatment outcomes, individuals were matched according to propensity score (figure 2), which increased the comparability of the groups.

### Discussion

Patients who were BFP beneficiaries were more likely to be younger, to be of mixed race, to use illicit drugs, to be less educated, and to have a lower individual monthly income, and were less likely to have health insurance than patients who were not BFP beneficiaries. Beneficiaries of BFP demonstrated greater social vulnerability providing justification for the programme. Families living in poverty not only have a low income, but have fewer opportunities to improve living conditions because their access to education is limited, which subsequently affects employment opportunities. In Brazil, more than 80% of adults (aged >25 years) from families who are beneficiaries of BFP are poorly educated (15-8% are illiterate and 65-3% do not complete primary school), which reduces employment opportunities and limits access to public utility services. *Our results also demonstrated an association between individuals who dropped out and poor education, unemployment, and use of illicit drugs. Our data highlight the social and economic disadvantages experienced by patients with tuberculosis (with or without BFP), supporting the rationale for interventions that address these potentially unmet social needs.

Although the proportion of patients in the BFP and non-BFP groups who were cured of tuberculosis was not significantly different (87% in the non-BFP group vs 88% in the BFP group, p=0.774), propensity score matching showed that rate of cure was 7-6% higher in the BFP group than the non-BFP group and the proportion of patients who dropped out was 7% lower in the BFP group than the non-BFP group. Additionally, the prospective study design, which included face-to-face interviews enabled the production of a directed acyclic graph with a large number of variables that demonstrated a causal association between exposure (BFP group) and outcome (outcome of tuberculosis treatment). This method enabled adjustment for a large number of comorbidities, such as those associated with socioeconomic status, environmental characteristics, and behaviour. In this analysis, a small difference was identified between the adjusted models and non-adjusted models for these variables. The comparison of adjusted and unadjusted models increased the reliability of our results.

Our results are consistent with those of previous studies, which investigated the effect of incentives as a method of social protection on the outcomes of tuberculosis treatment in low-income countries. A study in Nigeria showed that patients with tuberculosis who received $15 per month during treatment had a success rate that was approximately 15% higher than those who

---

**Table 3**: Unadjusted and adjusted multinomial logistic regression analysis of the association of being a beneficiary of the Bolsa Familia Programme and tuberculosis treatment outcomes.

<table>
<thead>
<tr>
<th>Coefficient</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cure</td>
<td>0.076</td>
<td>0.037 to 0.116</td>
</tr>
<tr>
<td>Dropout</td>
<td>-0.070</td>
<td>-0.105 to -0.036</td>
</tr>
<tr>
<td>Death</td>
<td>-0.002</td>
<td>-0.021 to -0.017</td>
</tr>
</tbody>
</table>

*Calculated with a logistic model using propensity score (estimated by the index of household goods, education, monthly individual income, unemployment, waste collection, house condition, current tobacco smoke, illicit drug use, comorbidities, private health insurance, and type of health-care service during treatment) matching in a 1:1 ratio.

---

**Table 4**: Average effect of being a beneficiary of the Bolsa Familia Programme on the outcome of tuberculosis treatment.

---

![Figure 2: Box plots of propensity scores before and after matching in the BFP and non-BFP groups.](image-url)
did not receive the incentive (p=0.003). This effect might have been partly due to the lower proportion of patients who were lost to follow-up in the group who received the incentive than the control group during the intervention period (20.2% vs 5.0%, p=0.001). Similar results were reported in a retrospective cohort study done in Moldova, which showed that provision of incentives (eg, cash, food vouchers, travel reimbursement) to patients with tuberculosis significantly improved treatment success rates by approximately 10%. Loss to follow-up (5% vs 10%, p=0.001), death (5% vs 6%, p=0.03), and failure (2% vs 5%, p=0.001) were also lower in the group receiving social protections than the group that did not receive them. A randomised controlled study in Peru evaluating the effect of conditional cash transfers (≤$230 per household) aimed at enhancing tuberculosis prevention and treatment, showed that cash transfers improved treatment outcomes: 64% of patients in the intervention group versus 53% in the control group were treated successfully (unadjusted odds ratio 1.6 [95% CI 1.0–2.6]). These studies demonstrate the potential impact of novel financial incentives or social support in improving tuberculosis treatment outcomes in a variety of social contexts.

A limitation of the study was non-random selection of BFP beneficiaries, which prevented comparison of the non-BFP and BFP groups because the effect of BFP could be associated with background characteristics that might vary between groups. We used a logistic model with propensity score matching to verify the average effect of BFP on the outcome of tuberculosis treatment as a strategy to overcome this limitation.

Our results show that BFP alone appears to be sufficient to have a direct effect on tuberculosis treatment outcome. One hypothesis is that this effect could increase even further if the programme specifically targeted patients with tuberculosis in addition to families of low socioeconomic status. Additionally, the number of BFP recipients in the population who have tuberculosis is low (only 13–1% of patients with tuberculosis are BFP beneficiaries), highlighting the need for implementation of health policies and programmes to reduce and minimise the negative effects of poverty on tuberculosis treatment outcomes. A key component of the WHO End Tuberculosis Strategy and the UN Sustainable Development Goals agenda is to improve the health and wellbeing of individuals through multisectorial interventions that jointly address issues of health and poverty. Modelling studies demonstrate that global expansion of social protections could decrease the incidence of tuberculosis by 76%. Social protection interventions, including expansion of existing programmes such as the BFP, could be a crucial for achieving these goals.

Contributors
BR-S, MNS, and ELNM conceptualised and designed the study. JGNO, BR-S, RLL, CMMS, WGDsf, KCD S, KVDa, GsDa, SMP, and ELNM collected data. KVDa, GsDa, and SMP developed the questionnaires. BR-S analysed and interpreted data. JGNO, RLL, CMMS, WGDsf, and KCD S drafted the manuscript. BR-S, MNS, PBS, LWR, CL, and ELNM revised the Article critically for important intellectual content. All authors approved the final version of the manuscript.

Declaration of interests
We declare no competing interests.

Acknowledgments
Data collection and monitoring were funded by the Brazilian Government through the National Scientific Council (404235/2012-3).

References